pipette
ESEspañol

A druggable chromatin vulnerability in suppressive neutrophils restores antitumor immunity

F. Yang, Y. Bao, Y. Qiao, G. Cruz, E. Young, R. Mannan, Y. Zhang, M. Goodrich, Y. Cao, J. Luo, R. Paturu, S. Mahapatra, J. C.-Y. Tien, R. Xu, M. Kobayashi, Y. Liu, A. Coleski, F. Su, X. Cao, S. J. Miner, L. Vatan, R. Sudharshan, A. Rao, S. Samajdar, C. Abbineni, M. Ramachandra, J. C. Piel, M. Hentemann, I. Kryczek, W. Zou, L. Xiao, A. M. Chinnaiyan

PreprintReal-world use

In the authors' words

Many cancers evade immunity by converting neutrophils into polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), but the chromatin mechanisms that maintain this pathological state remain unclear. Here we show that tumor-induced suppressive neutrophils depend on mSWI/SNF chromatin remodeling. Two orally bioavailable mSWI/SNF ATPase antagonists, a degrader and a catalytic inhibitor, produced immune-dependent tumor control across syngeneic models, including tumors resistant to PD-1 blockade, and enhanced checkpoint therapy without overt toxicity. Treatment rapidly depleted intratumoral PMN-MDSCs, restored functional CD8+ T cells, and blocked tumor explant-induced expansion and suppressive activity of mouse and human PMN-MDSCs. mSWI/SNF antagonism collapsed chromatin accessibility and PU.1/C/EBP{beta} occupancy at regulatory elements that sustain PMN-MDSC identity. Thus, suppressive neutrophils harbor a druggable chromatin vulnerability that can be exploited to restore cancer immunity.

Main resultThe abstract does not state a limitation.

Appeared: Tuesday, September 29. bioRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.09.26.754703